Clinical trials: Locally Advanced Colorectal Cancer
Anal Squamous Cell Carcinoma
Adaptive Radiation in Anal Cancer
This is a 20 patient pilot study to examine the feasibility of dose-adapted radiation therapy for the treatment of locally advanced anal squamous cell cancer.
- Trial name
- NCT05838391
- Testing
- Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery, Mitomycin-C, 5-Fluorouracil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Colonic Neoplasms, Neoadjuvant Therapy
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced Microsatellite Stable (MSS) colon cancer.
- Conditions
- Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- NCT06124378
- Testing
- Tislelizumab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Melanoma, Non-Small Cell Lung Cancer
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in…
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT03289962
- Testing
- Autogene cevumeran, Atezolizumab
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 273 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer
Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer
Investigators propose to assess, retrospectively (from 1/7/2009) and prospectively (up to 31/12/2013,) the safety and tolerability profile (number of participants with adverse events) of standard chemotherapy and anti-angiogenic…
- Trial name
- NCT01811108
- Where
- 6 sites in Greece
- Volunteers
- 670 people
- Sponsor
- Hellenic Oncology Research Group
Rectal Cancer
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the…
- Trial name
- NCT03516708
- Testing
- Epacadostat, Short-course radiation therapy, CAPOX chemotherapy
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Washington University School of Medicine
Rectal Cancer, Rectal Adenocarcinoma
A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer
PRIME-RT is an open label, multi-centre phase II randomised trial with 1:1 allocation between arm A and arm B. The principal research question is whether the addition of durvalumab to FOLFOX chemotherapy and radiation treatment…
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma, Rectal Neoplasms
- Trial name
- PRIME-RT (NCT04621370)
- Testing
- Durvalumab, FOLFOX, Short Course Radiotherapy (Arm A)
- Volunteers
- 48 people
- Sponsor
- Liz-Anne Lewsley
Rectal Neoplasms
Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer
Locally advanced rectal cancer (T3, T4 or lymph node positive tumors) are conventionally treated with 5FU / capecitabine based chemoradiation prior to surgical resection.
- Trial name
- NCT02137356
- Testing
- standard dose pelvic radiation therapy, standard dose capecitabine, dose-escalated selinexor treatment
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Sheba Medical Center
Anal Cancer, Anal Carcinoma
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
The RADIANCE multicenter, randomized phase II trial will assess the efficacy of durvalumab, a PD-L1 immune checkpoint inhibitor, in combination with primary mitomycin C (MMC)/5-fluorouracil (5-FU)-based radiochemotherapy (RCT) in…
- Conditions
- Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II
- Trial name
- RADIANCE (NCT04230759)
- Testing
- Chemotherapy, Radiation, Durvalumab
- Where
- 25 sites in Austria, Germany and 1 more
- Volunteers
- 180 people
- Sponsor
- Goethe University
Rectal Cancer
Induction Chemotherapy for Locally Advanced Rectal Cancer
Despite developments in the multidisciplinary treatment of patients with locally advanced rectal cancer (LARC), such as the introduction of total mesorectal excision (TME) by Heald et al.
- Trial name
- MEND-IT (NCT04838496)
- Testing
- FOLFOXIRI Protocol
- Where
- 13 sites in Netherlands
- Volunteers
- 128 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Locally Advanced, High-Risk
Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer
This is a single arm, open-label, prospective clinical trial to evaluate the combination of neoadjuvant short-course radiotherapy and toripalimab (PD-1 antibody) for locally advanced rectal cancer (LARC) patients with high risk…
- Conditions
- Locally Advanced, High-Risk, Rectal Cancer, MSS
- Trial name
- NCT05877573
- Testing
- Toripalimab, short-term radiotherapy, Oxaliplatin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Nanfang Hospital, Southern Medical University